---
title: Assessment of Renal Vasculature and Function with Ferumoxytol-enhanced Magnetic Resonance Imaging
nct_id: NCT05045872
overall_status: COMPLETED
phase: PHASE1
sponsor: The First Affiliated Hospital with Nanjing Medical University
study_type: INTERVENTIONAL
primary_condition: Chronic Kidney Diseases
countries: China
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT05045872.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT05045872"
ct_last_update_post_date: 2024-09-25
last_seen_at: "2026-05-12T06:26:24.385Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Assessment of Renal Vasculature and Function with Ferumoxytol-enhanced Magnetic Resonance Imaging

**Official Title:** Clinical Study of Domestic Polysaccharide Superparamagnetic Iron Oxide Nanoparticle Injection for Renal Contrast-enhanced Magnetic Resonance Imaging

**NCT ID:** [NCT05045872](https://clinicaltrials.gov/study/NCT05045872)

## Key Facts

- **Status:** COMPLETED
- **Phase:** PHASE1
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 44
- **Lead Sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Collaborators:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Conditions:** Chronic Kidney Diseases
- **Start Date:** 2021-09-17
- **Completion Date:** 2024-09-03
- **CT.gov Last Update:** 2024-09-25

## Brief Summary

Conventional contrast-enhanced magnetic resonance imaging is typically performed with extracellular gadolinium chelates, which is often limited in patients with CKD owing to the risk of nephrogenic systemic fibrosis. Ferumoxytol, a novel contrast medium, can be used as an "off-label" contrast agent for magnetic resonance imaging. During the last decade, ferumoxytol has gained appeal as an MRI contrast agent in patients with estimated glomerular filtration rates \<30mL/min and there are reports in the literature for its safe use and utility in both adult and pediatric patients with CKD. The study is designed to evaluate the diagnostic performance of ferumoxytol-enhanced magnetic resonance imaging in patients suspected of renal artery stenosis, investigate the correlation between renal cortical T2\*(T2\*=1/R2\*) and renal function, and develop an automatic algorithms for renal vessel segmentation.

## Detailed Description

This study is a single-center, prospective, controlled and diagnostic clinical trial to evaluate renal vasculature and renal function with ferumoxytol-enhanced magnetic resonance imaging using domestic polysaccharide superparamagnetic iron oxide injection as the contrast agent. This study will enroll 40 patients with or without renal impairment that are expected to undergo renal artery angiography in China. The investigators will record the baseline data of patients after admission. Patients will receive enhanced renal magnetic resonance imaging with polysaccharide superparamagnetic iron oxide nanoparticle to assess renal vasculature and renal function. The related laboratory indices will be reviewed at 24-72 h after magnetic resonance imaging, and then patients will receive renal angiography. The indices will be reexamined at 1 month and 3 months after magnetic resonance imaging. In order to evaluate the safety of polysaccharide superparamagnetic iron oxide nanoparticle, patients will detect iron levels in peripheral and tissue before and after the examination. The results of MR imaging including image quality, degree of vascular stenosis, and quantitative T2\* values of the renal cortex will be evaluated independently by two experienced radiologists. The degree of stenosis of the same vessels assessed by Quantitative Coronary Analysis (QCA) will be used for comparison with MR results. All clinical adverse events will be recorded by investigators.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 75 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Age ≧ 18 years, \< 75 years;
* Patients who planned renal angiography (hypertension 、renal failure、atherosclerosis）;
* Patients with normal renal function or CKD stage 1-5(Patients diagnosed with CKD as defined in the KDIGO Clinical Practice Guidelines for the Evaluation and Management of Chronic Kidney Disease 2012 Edition);
* Patients themselves or authorized families to sign informed consent voluntarily.

Exclusion Criteria:

* Patients who were allergic to iodine contrast agent or had allergic history or allergic constitution to iron and dextran;
* Patients who can't accept magnetic resonance examination because of psychological ( such as Claustrophobia ) or physical reasons ( such as metal retention in the body );
* Malignancies or other comorbid conditions with life expectancy less than 1 year;
* Pregnant or lactating women;
* Hearing impaired persons;
* Cardiac function grade III-IV;
* Patients who were taking other iron agents orally or intravenously;
* Patients with hemosiderin deposition or hemochromatosis;
* Patients with acute coronary syndromes;
* Any other patients that researcher deems it's unsuitable to be admitted.
```

## Arms

- **ferumoxytol-enhanced renal magnetic resonance imaging** (EXPERIMENTAL) — Patients will receive ferumoxytol-enhanced renal magnetic resonance imaging before renal angiography. Ferumoxytol (510 mg/17mL; Chia Tai Tianqing Pharmaceutical Group Co Ltd, Nanjing, China) will be diluted at 1:4 (v/v) and intravenously infused into the antecubital vein at a dose of 3 mg/kg with an infusion speed of 0.07 mL/s.

## Interventions

- **domestic polysaccharide superparamagnetic iron oxide nanoparticle** (DRUG) — Patients will receive contrast-enhanced renal magnetic resonance imaging with polysaccharide superparamagnetic iron oxide nanoparticle before renal angiography. Patients received intravenous polysaccharide superparamagnetic iron oxide nanoparticle before magnetic resonance imaging.

## Primary Outcomes

- **the degree of renal artery stenosis** _(time frame: baseline and after intervention)_ — Degree of renal artery stenosis assessed by Magnetic Resonance Imaging and renal angiography
- **quantitative cortical T2* value** _(time frame: baseline and after intervention)_ — the quantitative T2\* value of the renal cortex will be measured bilaterally at the upper and lower poles by drawing six equal-sized, non-overlapping operator-dependent regions of interest (ROI) to calculate average quantitative T2\* values.
- **change of hemoglobin level** _(time frame: baseline,72 hours,30 days,3 months)_ — hemoglobin examination of patients before and after examination to evaluate anemia.
- **serum creatinine** _(time frame: baseline,72 hours,30 days,3 months)_ — serum creatinine examination of patients before and after examination to evaluate kidney function.
- **Urine routine** _(time frame: baseline,72 hours,30 days,3 months)_ — Urine routine examination of patients before and after examination to evaluate kidney function.
- **24-hour urine biochemistry** _(time frame: baseline,72 hours,30 days,3 months)_ — 24-hour urine biochemistry examination of patients before and after examination to evaluate kidney function.
- **Retinol binding protein** _(time frame: baseline,72 hours,30 days,3 months)_ — Retinol binding protein examination of patients before and after examination to evaluate kidney function.
- **Neutrophil gelatinase-associated lipocalin** _(time frame: baseline,72 hours,30 days,3 months)_ — Neutrophil gelatinase-associated lipocalin examination of patients before and after examination to evaluate kidney function.
- **Serum iron** _(time frame: baseline,72 hours,30 days,3 months)_ — Determination of serum iron before and after MRA to evaluate the changes of iron content in peripheral blood.
- **Ferritin** _(time frame: baseline,72 hours,30 days,3 months)_ — Determination of serum ferritin before and after MRA to evaluate the changes of iron content in peripheral blood.
- **Transferrin** _(time frame: baseline,72 hours,30 days,3 months)_ — Determination of serum transferrin before and after MRA to evaluate the changes of iron content in peripheral blood.
- **serum cystatin C** _(time frame: baseline,72 hours,30 days,3 months)_ — Determination of serum cystatin C before and after examination to evaluate the changes of renal function.

## Locations (1)

- First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China

## Recent Field Changes (last 30 days)

- `design.enrollmentCount` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.first affiliated hospital of nanjing medical university|nanjing|jiangsu|china` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT05045872.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT05045872*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*